Determination of the median effective dose of remimazolam besylate to inhibit cardiovascular response to laryngeal mask insertion in elderly patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300067838

Enrollment

Unknown

Registered

2023-01-29

Start date

2023-05-24

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anesthesia induction

Interventions

Test group:Dose of remimazolam

Eligibility

Sex/Gender

All

Age

60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Elective surgery under general anesthesia with laryngeal mask airway was performed; 2. Aged 60 years or older; 3. ASA grade I-III; 4. BMI of 18-30 kg/m2.

Exclusion criteria

Exclusion criteria: 1. Severe hypertension (SBP >= 180 MMHG or DBP >= 110 MMHG), heart rate >= 110 beats /min; 2. Neuropsychiatric disorders; 3. Benzodiazepines were used within 1 month; 4. Have contraindications or allergies to benzodiazepines; 5. Estimated difficult airway; 6. Had a history of allergy to remimazolam.

Design outcomes

Primary

Measure	Time frame
Dose of remimazolam;	—

Secondary

Measure	Time frame
heart rate;blood pressure;cerebral state index;	—

Countries

China

Contacts

Public ContactNie Huang

The First Affiliated Hospital, the Air Force Medical University

13201630298@163.com+86 132 0163 0298

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026